Fate Therapeutics (FATE) Accounts Payables (2012 - 2026)
Fate Therapeutics' (FATE) quarterly Accounts Payables came in at $3.3 million in Q1 2026, down 21.79% YoY from $4.2 million in Q1 2025, and up 23.38% on a QoQ basis from $2.7 million in Q4 2025.
Fate Therapeutics (FATE) Accounts Payables (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 15 years of Accounts Payables data on file, last reported at $3.3 million in Q1 2026.
- Quarterly Accounts Payables fell 21.79% year-over-year to $3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (down 21.79% YoY) and the FY2025 annual result came in at $2.7 million, down 71.64% from the prior year.
- Accounts Payables improved to $3.3 million in Q1 2026, from $2.7 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $11.4 million in Q1 2022 to a low of $2.7 million in Q4 2025.
- A 5-year average of $6.5 million and a median of $6.3 million in 2024 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2024 — Accounts Payables surged 98.45% — and 2025, when it plunged 71.64%.
- Tracing FATE's Accounts Payables over 5 years: stood at $8.3 million in 2022, then slumped by 42.9% to $4.7 million in 2023, then soared by 98.45% to $9.4 million in 2024, then sank by 71.64% to $2.7 million in 2025, then advanced by 23.38% to $3.3 million in 2026.
- The last three Accounts Payables figures came in at $3.3 million (Q1 2026), $2.7 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | 3.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.28 Mn |
| Dec 31, 2025 | 2.66 Mn |
| Sep 30, 2025 | 3.50 Mn |
| Jun 30, 2025 | 4.04 Mn |
| Mar 31, 2025 | 4.19 Mn |
| Dec 31, 2024 | 9.37 Mn |
| Sep 30, 2024 | 6.35 Mn |
| Jun 30, 2024 | 5.50 Mn |
| Mar 31, 2024 | 6.77 Mn |
| Dec 31, 2023 | 4.72 Mn |
| Sep 30, 2023 | 5.71 Mn |
| Jun 30, 2023 | 7.51 Mn |
| Mar 31, 2023 | 9.86 Mn |
| Dec 31, 2022 | 8.27 Mn |
| Sep 30, 2022 | 9.59 Mn |
| Jun 30, 2022 | 8.42 Mn |
| Mar 31, 2022 | 11.44 Mn |
| Dec 31, 2021 | 8.61 Mn |
| Sep 30, 2021 | 6.44 Mn |
| Jun 30, 2021 | 5.77 Mn |